blocker atp

Vonoprazan fumarate (TAK-438) is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase.

JTV-519 Formate is a Ca2+-dependent blocker of sarcoplasmic reticulum Ca2+-stimulated ATPase (SERCA). JTV-519 Formate is also a partial agonist of ryanodine receptors in striated muscle. JTV-519 Formate exhibits antiarrhythmic and cardioprotective properties.

5-Hydroxydecanoate sodium is a selective ATP-sensitive K+ (KATP) channel blocker with an IC50 of approximately 30 μM and a substrate for mitochondrial outer membrane acyl-CoA synthetase, possessing antioxidant properties.

A-803467 is a selective NaV1.8 channel blocker.

Gliclazide is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Ethyl tosylcarbamate is an intermediate in the synthesis of Gliclazide (G409877).

Tegoprazan is a potassium-competitive acid blocker and is a potent, oral active, and highly selective inhibitor of gastric H+/K+-ATPase. That could control gastric acid secretion and motility (IC50: ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro).

Clamikalant sodium is a non-selective, ATP-sensitive potassium (KATP) channel blocker that can be used to study cardiac arrhythmias.

Glisoxepide is a sulphonamide derivative and is an orally available nonselective K(ATP) channel blocker. It has antihyperglycemic activity and cardiovascular regulation effect.

Tilisolol is a nonselective blocker of beta-adrenergic. Tilisolol hydrochloride dilates coronary arteries through an ATP-sensitive K(+)-channel opening mechanism in dogs.

Glibornuride, a blocker of ATP-sensitive K+ channels (pKi: 5.75), inhibits high-affinity [3H]-glibenclamide binding with potencies corresponding to its K+ channel activity.

TAT-Gap19(I130A) is a control peptide for TAT-Gap19, a Cx43 hemichannel blocker. TAT-Gap19(I130A) consists of TAT-GAP19 with a I130A amino acid residue change at a key residue for GAP19 activity. In C6 glioma cells expression Cx43, TAT-GAP19(1130A) does not inhibit [Ca2+]i-triggered ATP release at 200 μM. TAT-Gap19(I130A) is cell permeable.

ZM-181037 is an ATP-sensitive potassium channel-blocker and a eukalemic diuretic.